US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy. The global Asthma Drugs market is valued at xx million US$ in 2020 is expected to reach xx million US$ by the end of 2029, growing at a CAGR of xx% during 2020-2029. This report focuses on Asthma Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Asthma Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, and Japan. At the company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
- Boehringer Ingelheim
- Teva Pharmaceutical
- Vectura Group
Segment by Regions
- North America
Segmentation By Medication Class
- Relvar/Breo Ellipta
Leukotriene Antagonists (LTA)
Inhaled Corticosteroids (ICS)
Short Acting Beta Agonists(SABA)
- Long Acting Beta Agonists (LABA)
Key Industry DevelopmentIn September 2020, GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate / umeclidinium / vilanterol 200/62.5/25mcg. The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US. The approval is an important advance for patients as it allows them to benefit from triple therapy by using one inhaler, once-a-day. Trelegy’s approval for the maintenance treatment of asthma in patients aged 18 years and older introduces a new paradigm for managing the approximately 30% of adult asthma patients who still experience symptoms despite being adherent to inhaled corticosteroids/ long-acting beta-agonist (ICS/LABA) combination therapy. In the US there are almost 20 million adults living with asthma and many of those continue to live with and adapt their lives around ongoing symptoms. FF/UMEC/VI is a combination of three molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler.
Table of Contents Executive Summary 1 Asthma Drugs Market Overview 1.1 Product Overview and Scope of Asthma Drugs 1.2 Asthma Drugs Segment by Type 1.2.1 Global Asthma Drugs Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Quick-relief Medications (Rescue Medications) 1.2.3 Medications for Allergy-induced Asthma 1.3 Asthma Drugs Segment by Application 1.3.1 Asthma Drugs Consumption Comparison by Application (2014-2025) 1.3.2 Allergic Asthma 1.3.3 Non-Allergic Asthma 1.3 Global Asthma Drugs Market by Region 1.3.1 Global Asthma Drugs Market Size Region 1.3.2 North America Status and Prospect (2014-2025) 1.3.3 Europe Status and Prospect (2014-2025) 1.3.4 China Status and Prospect (2014-2025) 1.3.5 Japan Status and Prospect (2014-2025) 1.3.6 Southeast Asia Status and Prospect (2014-2025) 1.3.7 India Status and Prospect (2014-2025) 1.4 Global Asthma Drugs Market Size 1.4.1 Global Asthma Drugs Revenue (2014-2025) 1.4.2 Global Asthma Drugs Production (2014-2025) 2 Global Asthma Drugs Market Competition by Manufacturers 2.1 Global Asthma Drugs Production Market Share by Manufacturers (2014-2019) 2.2 Global Asthma Drugs Revenue Share by Manufacturers (2014-2019) 2.3 Global Asthma Drugs Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Asthma Drugs Production Sites, Area Served, Product Types 2.5 Asthma Drugs Market Competitive Situation and Trends 2.5.1 Asthma Drugs Market Concentration Rate 2.5.2 Asthma Drugs Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Asthma Drugs Production Market Share by Regions 3.1 Global Asthma Drugs Production Market Share by Regions 3.2 Global Asthma Drugs Revenue Market Share by Regions (2014-2019) 3.3 Global Asthma Drugs Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America Asthma Drugs Production 3.4.1 North America Asthma Drugs Production Growth Rate (2014-2019) 3.4.2 North America Asthma Drugs Production, ... | read more...